Related Experiment Video
Updated: Jun 3, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Risk modeling strategies for pharmacogenetic studies
Andrea L Jorgensen1, Munir Pirmohamed
1Department of Biostatistics, University of Liverpool, Shelley's Cottage, Brownlow Street, Liverpool, L69 3GS, UK. a.l.jorgensen@liv.ac.uk
Pharmacogenomics
|April 1, 2011
Summary
Pharmacogenetic risk models show promise but require proven predictive capability and superiority over alternatives before clinical adoption. Rigorous evaluation methods are essential for demonstrating their real-world benefit.
Area of Science:
- Pharmacogenetics
- Clinical Decision Support
- Biostatistics
Background:
- Pharmacogenetic risk models hold potential for personalized treatment decisions.
- Limited evidence from clinical trials hinders their widespread adoption in practice.
- Lack of robust validation and comparative studies impedes clinical integration.
Purpose of the Study:
- To emphasize the necessity of proving predictive capability for pharmacogenetic models.
- To advocate for demonstrating model superiority against the best alternative methods.
- To guide the evaluation of pharmacogenetic models prior to clinical utility studies.
Main Methods:
- Utilizing Decision Curve Analysis for evaluating clinical implications in binary outcomes.
- Recommending Net Reclassification Improvement and Integrated Discrimination Difference for model comparison.
- Acknowledging straightforward performance assessment for continuous outcomes like therapeutic dosing.
Main Results:
- Current methods for evaluating pharmacogenetic models may not fully capture clinical utility.
- Specific statistical approaches are recommended for robust model validation and comparison.
- The assessment of models for continuous outcomes is generally more direct.
Conclusions:
- Rigorous validation of predictive capability and superiority is crucial for pharmacogenetic models.
- Decision Curve Analysis and reclassification metrics offer superior evaluation frameworks.
- Evidence-based validation is key to enabling the clinical translation of pharmacogenetic tools.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...